Macrophage-derived inflammatory mediator (MIP-2)

An antibody to an inflammatory cytokine is disclosed. The inflammatory cytokine has been isolated from cells that have been incubated with a stimulator material. The inflammatory cytokine is capable of binding to heparin, inducing localized inflammation characterized by polymorphonuclear cell infiltration when administered subcutaneously and having potent in vitro chemotactic activity while inducing little or no in vitro chemokinesis in polymorphonuclear cells, while lacking the ability to suppress the activity of the anabolic enzyme lipoprotein lipase, cause the cytotoxicity of cachectin/TNF-sensitive cells, stimulate the blastogenesis of endotoxin-resistant C3H/HeJ thymocytes, or induce the production of cachectin/TNF by primary thioglycbllate-elicited mouse macrophage cells. A particular inflammatory cytokine has been isolated and its cDNA has been sequenced. The sequence predicts a cDNA of 74 amino acids in length and a molecular weight of 7,908. Diagnostic and therapeutic utilities are proposed, and testing procedures, materials in kit form, recombinant materials and procedures, and pharmaceutical compositions comprising an antibody to the cytokine are likewise set forth.

Skip to:  ·  Claims  ·  References Cited  · Patent History  ·  Patent History

Claims

1. An antibody to an inflammatory cytokine, which inflammatory cytokine elutes from a heparin affinity column in a 0-2 M NaCl gradient at 0.75 M NaCl, is cationic under physiological conditions, and is characterized by inducing localized intimation characterized by polymorphonuclear cell infiltration when administered subcutaneously and having potent in vitro chemotactic activity while inducing little or no in vitro chemokinesis in polymorphonuclear cells, while lacking the ability to suppress the activity of the anabolic enzyme lipoprotein lipase, cause the cytotoxicity of cachectin/TNF-sensitive cells, stimulate the blastogenesis of endotoxin-resistant C3H/Hel thymocytes, or induce the production of cachectin/TNF by primary thioglycollate-elicited mouse macrophage cells, which cytokine has an apparent molecular mass of approximately 6000 Daltons by SDS-PAGE, and fractionates from a gel filtration cokunn with an apparent molecular mass of approximately 10,000 Daltons.

2. The antibody of claim 1 comprising a polyclonal antibody.

3. The antibody of claim 1 comprising a monoclonal antibody.

4. An hybridoma cell line that produces a monoclonal antibody according to claim 3.

5. The antibody of claims 1 labeled with a detectable label.

6. The antibody of claim 5 wherein the label is selected from the group consisting of an enzyme, a chemical which fluoresces, and a radioactive element.

7. The antibody of claim 1, wherein the inflammatory cytokine has partial N-terminal sequences as depicted in FIG. 6.

8. The antibody of claim 1, wherein the inflammatory cytokine has an amino acid sequence as depicted in FIG. 7.

Referenced Cited
U.S. Patent Documents
3654090 April 1972 Schuurs et al.
3850752 November 1974 Schuurs et al.
4603106 July 29, 1986 Cerami et al.
4961926 October 9, 1990 Gabrilove
5145676 September 8, 1992 Fahey, III et al.
Foreign Patent Documents
WO 83/00930 March 1983 WOX
Other references
  • A.M. Campbell, Monoclonal Antibody Technology, Elsevier Science Publishers, B.V., 1984, pp. 1-32. S.D. Wolpe et al, Proc. Natl. Acad. Sci. USA, 86, 612-616, 1989. Sherry et al. (1992) Cytokines 4: 117-30. Sherry et al. (1991) Curr. Opin. Immunol. 3: 56-60. Widmer et al. (1991) J. Immunol. 146: 4031-40. Baker et al. (1990) Nucl. Acids Res. 18: 6453. Dexter et al. (1990) Nature 344: 380-1. Graham et al. (1990) Nature 344: 442-4. Haskill et al. (1990) Proc. Natl. Acad. Sci. USA 87: 7732-6. Davatelis et al. (1989) Science 243: 1066-8. Wolpe et al. (1989) FASEB J. 3: 2565-73. Yoshimura et al. (1989) FEBS Letts. 224:487-93. Kampschmidt, R.F. (1978) J. Ret. Soc. 23:287-97. Dinarello et al. (1977) Proc. Natl. Acad. Sci. USA 74: 4624-7. Matsushima et al. (1988) J. Exp. Med. 167: 1883-93. Peveri et al. (1988) J. Exp. Med. 167: 1547-59. Van Damme et al. (1988) J. Exp. Med. 167: 1364-76. Sherry et al. (1988) J. Exp. Med. 168: 2251-9. Barney et al. (1980) Fever: International Symposium, Dallas TX, Apr. 11-12, 1979. XII+263 P, ISBN 0-89004-451-1(08877) pp. 111-122. Kampschmidt et al. (1980) J. Lab. Clin. Med. 95: 616-23. Sipe et al. (1979) J. Exp. Med. 150: 597-606. Walz et al. (1987) Bioch. Biophys. Res. Comm. 149: 755-61. Wolpe et al. (1987) in The inhibitors of hamatopoiesis. Najman et al. eds. pp. 197-200. Yoshimura et al. (1987) J. Immunol. 139: 788-93. Yoshimura et al. (1987) Proc. Natl. Acad. Sci. USA 84: 9233-7. Torti et al. (1985) Science 229: 867-9. Beutler et al. (1985) Science 229: 869-71. Mahoney et al. (1985) J. Immunol. 134: 1673-1675. Beutler et al. (1985) Nature 316: 552-4. Hotez et al. (1984) Parasite Immunol. 6:203-9. Cochran et al. (1983) Cell 33: 937-47. Kawakami et al. (1982) Proc. Natl. Acad. Sci. USA: 79: 912-16.
Patent History
Patent number: 5717074
Type: Grant
Filed: Jun 7, 1995
Date of Patent: Feb 10, 1998
Assignee: The Rockefeller University (New York, NY)
Inventors: Stephen D. Wolpe (Arlington, MA), Anthony Cerami (Shelter Island, NY), Barbara Sherry (New York, NY)
Primary Examiner: David Saunders
Law Firm: Klauber & Jackson
Application Number: 8/480,085